GGrantIndex
← Leaderboards

Robert W. Mahley

J. David Gladstone Institutes

$13,768,272
Attributed
$18,468,541
Total exposure
14
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $6M · FY200621
$10M$7.5M$5M$2.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21

Funding mix

By agency

NIH$19,960,937 · 15

By mechanism

R44$4,731,346 · 2
RF1$4,669,193 · 1
P01$3,044,970 · 4
U01$2,200,895 · 1
C06$2,093,817 · 1
R56$1,559,061 · 2

Top collaborators

Most similar at J. David Gladstone Institutes

Same institution · by research overlap

Others in their field

Top investigators on “Alzheimer&Apos

Research focus

Alzheimer&AposApolipoprotein EProtein IsoformsS DiseaseApolipoprotein E-4NeuronsCellsApolipoprotein E-3AffectNeurodegenerative DisordersBrainGenetic Risk FactorPathway InteractionsImpairmentLeadBaseImpaired CognitionPreventAllelesEventAge Of OnsetLearningProteinsStructure

Grant awards (28)

Develop GABAergic Neuron Protectors for Treating ApoE4-Related Alzheimer's Disease$1,086,082
R44 · FY2021 · AG · contact PI
Develop GABAergic Neuron Protectors for Treating ApoE4-Related Alzheimer's Disease$1,079,582
R44 · FY2020 · AG · contact PI
Somatostatin (SST)-GABAergic Interneuron Therapy for Alzheimer's Disease with ApoE4$948,584
R44 · FY2020 · AG · contact PI
Proteomic and Genetic Approaches Defining Apolipoprotein E4 Neuropathologic Mechanisms$4,669,193
RF1 · FY2019 · AG · contact PI
Somatostatin (SST)-GABAergic Interneuron Therapy for Alzheimer's Disease with ApoE4$982,084
R44 · FY2019 · AG · contact PI
Develop GABAergic Neuron Protectors for Treating ApoE4-Related Alzheimer's Disease$342,592
R44 · FY2019 · AG · contact PI
Apolipoprotein E and Alzheimer's Disease: Mitochondrial Dysfunction and Neurodegeneration$782,374
R56 · FY2018 · AG · contact PI
ApoE2 and Alzheimer's Disease: Structural and Functional Roles in CNS Metabolism$776,687
R56 · FY2018 · AG · contact PI
Somatostatin (SST)-GABAergic Interneuron Therapy for Alzheimer's Disease with ApoE4$292,422
R44 · FY2018 · AG · contact PI
Targeting ApoE4 as a Therapeutic Strategy for Alzheimer's Disease$530,070
U01 · FY2014 · AG · contact PI
Targeting ApoE4 as a Therapeutic Strategy for Alzheimer's Disease$818,590
U01 · FY2013 · AG · contact PI
ApoE4 Structure Correctors as a Therapeutic Approach for Alzheimers Disease$45,517
R03 · FY2013 · DA · contact PI
Targeting ApoE4 as a Therapeutic Strategy for Alzheimer's Disease$852,235
U01 · FY2012 · AG · contact PI
Role of apoE structure and metabolism in neurodegeneration$372,595
R01 · FY2012 · AG · contact PI
ApoE4 Structure Correctors as a Therapeutic Approach for Alzheimers Disease$46,925
R03 · FY2012 · DA · contact PI
Role of apoE structure and metabolism in neurodegeneration$372,595
R01 · FY2011 · AG · contact PI
APOLIPOPROTEIN E IN NEUROBIOLOGY: CELLULAR MECHANISMS$315,162
P01 · FY2007 · AG · contact PI
APOLIPOPROTEIN E IN NEUROBIOLOGY: CELLULAR MECHANISMS$218,268
P01 · FY2006 · AG · contact PI
Targeting Apolipoprotein E4-related Neuropathology$251,460
R21 · FY2004 · NS
EXTRAMULAR RESEARCH FACILITIES CONSTRUCTION$2,093,817
C06 · FY2003 · RR
Targeting Apolipoprotein E4-related Neuropathology$212,563
R21 · FY2003 · NS
Genetic Determinants: Low HDL, High Triglycerides, Obes*$180,000
R01 · FY2003 · HL
Genetic Determinants: Low HDL, High Triglycerides, Obes*$180,000
R01 · FY2002 · HL
GENETIC ALTERATIONS ON LIPOPROTEINS AND ATHEROSCLEROSIS$1,492,396
P01 · FY2001 · HL
CORE--METABOLISM AND PATHOLOGY$243,516
P01 · FY2001 · HL
APOLIPOPROTEIN E ISOFORM EFFECTS IN TRANSGENIC ANIMALS$243,516
P01 · FY2001 · HL
CORE--METABOLISM AND PATHOLOGY$266,056
P01 · FY2000 · HL
APOLIPOPROTEIN E ISOFORM EFFECTS IN TRANSGENIC ANIMALS$266,056
P01 · FY2000 · HL